Serum interleukin-8 levels may predict relapse in brucellosis

To investigate whether cytokines are effective in predicting relapses among patients with acute brucellosis. Materials and methods: This trial was conducted in 42 patients who were being followed-up with diagnosis of acute brucellosis. Serum samples were obtained on days 0 and 45. In patients whose clinical symptoms recurred within a year of treatment and exhibited infectious parameters in compliance with brucellosis, a Rivanol standard tube agglutination (STA) test was performed and the diagnosis of relapse was based on brucella immunoglobulin M (IgM). Serum samples were evaluated for various parameters, namely tumor necrosis factor-alpha (TNF-a), interferon-gamma (IFN-g), interleukin 2 (IL-2), IL-4, IL-6, IL-8, IL-10, and soluble IL-2 receptor (sIL-2R). Results: Relapse was seen in 7 patients. No difference was found between relapsing patients (RPs) and fully recovered patients (FRPs) in terms of age, sex, leukocyte levels, or C-reactive protein (CRP) values. Comparison of TNFa, IFNg, IL-2, IL-4, IL-6, IL-8, and IL-10 values on day 0 (day of enrollment) revealed 2-fold higher IL-8 values among RPs compared to FRPs. IL-8 was suggested as significant in terms of predicting relapse. Conclusion: Diagnosis and treatment of relapsing cases in acute brucellosis have not yet been clarified. Predicting relapse by certain laboratory evaluations may be beneficial in preventing clinical relapses by rearranging treatment and monitoring strategies of patients.

Anahtar Kelimeler:

Key words: Acute brucellosis, relapse, cytokines

Serum interleukin-8 levels may predict relapse in brucellosis

Keywords:

Key words: Acute brucellosis, relapse, cytokines,

PDF

___

Doğanay M, Aygen B. Human brucellosis: an overview. Int Infect Dis 2003; 7: 173-82.
Odbıleg R, Pruevtseren B, Gantsetseg D, Boldbaatar B, Buyannemekh T, Galmandakh Z et al. Cytokine responses in camels (Camelus bactrianus) vaccinated with brucella abortus strain 19 vaccine. J Vet Med Sci 2008; 70: 197-201. 8. Skendros P, Pappas G, Boura P. Cell-mediated immunity in human brucellosis. Microbes Infect 2011; 13: 134-42. 9. Akbulut H, Çelik I, Akbulut A. Cytokine levels in patients with brucellosis and their relations with the treatment. Indian J Med Microbiol 2007; 25: 387-90.
Grossi C, Lydiard P. Cells Involved in Immune Responses. In: Roitt I, Brostoff J, Male D, editors. Immunology. 4th ed. Mosby: Year Book Europe Limited; 1993. p.2.2-2.20.
Solera J, Martinez-Alfaro E, Espinosa A, Castillejelos ML, Geijo P, Rodriguez-Zapata M. Multivariate model for predicting relapse in human brucellosis. Journal of Infection 1998; 36: 85-92.
Ariza J, Corredoira J, Pallares R, Viladrich PF, Rufi G, Pujol M, Gudiol F. Characteristics of and risk-factors for relapse of brucellosis in humans. Clin Infect Dis. 1995; 20: 1241-9.
Wuyts A, Proost P, Damme JV. Interleukin-8 and Other CXC Chemokines. In: Th omson AW, editor. Th e cytokine handbook. London, UK: Academic Press; 1998. p.271-313.
Refi k M, Mehmet N, Durmaz R, Ersoy Y. Cytokine profi le and nitric oxide levels in sera from patients with brucellosis. Braz J Med Biol Res 2004; 37: 1659-63.
Delpino MV, Barrionuevo P, Scian R, Fossati CA, Baldi PC. Brucella-infected hepatocytes mediate potentially tissue damaging immune responses. J Hepatol 2010; 53: 145-54.
Rafi ei A, Ardestani SK, Kariminia A, Keyhani A, Mohraz M, Amirkhani A. Dominant Th 1 cytokine production in early onset of human brucellosis followed by switching towards TH2 along prolongation of disease. J Infect 2006; 53: 315-24.
Demirdağ K, Ozden M, Kalkan A, Godekmerdan A, Kiliç SS. Serum cytokine levels in patients with acute brucellosis and their relation to the traditional infl ammatory markers. FEMS Immunol Med Microbiol 2003; 39: 149-53.
Ahmed K, Matrouk A, Martinez G, Oishi K, Rotimi VO, Nagatake T. Increased serum levels of interferon-alfa and interleukın-12 during human brucellosis. Am J Trop Med Hyg 1999; 61: 425-7.
Palmer MV, Elsasser TH, Cheville NF. Tumor necrosis factor- alpha in pregnant cattle aft er intravenous or subcutaneous vaccination with Brucella abortus strain RB51. Am J Vet Res 1998; 59: 153-6.
Makis A, Galanakis E, Hatzimichael CE, Papadopoulou ZL, Siamopoulou A, Bourantas KL. Serum levels of interlokin-2 receptor alpha as a predictor of outcome in Brucellosis. J Infect 2005; 51: 206-10.
Chomarat P, Rybak ME, Banchereau J. Interleukin-4. In: Th omson A, editor. Th e cytokine handbook. 1st ed. London, UK: Academic Press; 1998. p.133-75.
Akbulut H, Kilic SS, Bulut V, Ozden M. Determination of intracellular cytokines produced by Th 1 and TH2 cells using fl ow cytometry in patients with brucellosis. FEMS Immunol Med Microbiol 2005; 45: 253-8.
Pasquali P, Adone R, Gasbarre LC, Pistoia C, Ciuchini F. Mouse cytokine profi les associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection. Infect Immun. 2001; 69: 6541-4.
Galanakis E, Makis A, Bourantas KL, Papadopoulou ZL. Interleukin-3 and interleukin-4 in chilhood brucellosis. Infection 2002; 30: 33-4.
Hirano T. Interleukin-6. In: Th omson AW. editor. Th e cytokine handbook. 1st ed. London, UK: Academic Press; 1998. p.197- 229.
Dornand J, Gross A, Lafont V, Liautard J, Oliaro J, Liautard JP. Th e innate immune response against brucella in humans. Vet Microbiol. 2002; 90: 383-94.
Malefyt RW, Moore KV. Interleukin-10. In: Th omson AW, editor. Th e cytokine handbook. 1st ed. London, UK: Academic Press; 1998. p.333-365.